167 related articles for article (PubMed ID: 38586203)
1. Intrapleural perfusion hyperthermia improves the efficiency of anti‑PD1 antibody‑based therapy for lung adenocarcinoma: A case report.
Wang X; Song J; Hu L; Ren G; Geng N; Song Z
Oncol Lett; 2024 May; 27(5):217. PubMed ID: 38586203
[TBL] [Abstract][Full Text] [Related]
2. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
3. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: a case report and review of literature.
Zhang Y; Zhang F; Zhao L; Fu X; Shang Y; Gao Q
BMC Gastroenterol; 2021 Oct; 21(1):399. PubMed ID: 34688262
[TBL] [Abstract][Full Text] [Related]
4. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
Gu YC; Liu Y; Xie C; Cao BS
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
[TBL] [Abstract][Full Text] [Related]
5. Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
Li X; Wu G; Chen C; Zhao Y; Zhu S; Song X; Yin J; Lv T; Song Y
Front Immunol; 2021; 12():760683. PubMed ID: 34966384
[TBL] [Abstract][Full Text] [Related]
6. Intrapleural interleukin-2-expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease.
Ekeke CN; Russell KL; Murthy P; Guo ZS; Soloff AC; Weber D; Pan W; Lotze MT; Dhupar R
J Thorac Cardiovasc Surg; 2022 Apr; 163(4):e313-e328. PubMed ID: 33485667
[TBL] [Abstract][Full Text] [Related]
7. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
8. A lung adenocarcinoma patient with
Xu F; Xiao C; Sun W; He Y; Chalela R; Masuda K; Ulivi P; Shen K; Shao Q; Xu J; Liu L
Ann Transl Med; 2022 Aug; 10(16):912. PubMed ID: 36111030
[TBL] [Abstract][Full Text] [Related]
9. Short-term outcomes of neoadjuvant sintilimab with chemotherapy in stage III non-small cell lung cancer: a case series.
Fan BS; Wang XT; Di SY; Zhao JH; Chen SY; Zhou SH; Yue CY; Song WA; Gong TQ
Transl Cancer Res; 2022 Jun; 11(6):1697-1704. PubMed ID: 35836545
[TBL] [Abstract][Full Text] [Related]
10. Case report: A lung squamous cell carcinoma patient with a rare
Zhu ZF; Bao XX; Shi HY; Gu XX
Front Oncol; 2024; 14():1283008. PubMed ID: 38357203
[TBL] [Abstract][Full Text] [Related]
11. Reversal of resistance to chemotherapy following anti-programmed cell death-1 immunotherapy in metastatic lung adenocarcinoma: A case report.
Liu X; Liu H; Luo S
Medicine (Baltimore); 2018 Dec; 97(49):e13427. PubMed ID: 30544423
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases.
Shen Q; Qu J; Sheng L; Gao Q; Zhou J
Front Oncol; 2021; 11():619371. PubMed ID: 34094904
[TBL] [Abstract][Full Text] [Related]
13. [Thoracic
Xiong Y; Zhang B; Nie LG; Wu SK; Zhao H; Li D; DI JT
Beijing Da Xue Xue Bao Yi Xue Ban; 2023 Apr; 55(2):351-356. PubMed ID: 37042149
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study.
Wan C; Zhang Y; Liu P; Mei X; Cheng G; Pang J; Chen S; Xu J; Malhotra J; Qian H; Du Y
J Thorac Dis; 2023 Oct; 15(10):5648-5657. PubMed ID: 37969256
[TBL] [Abstract][Full Text] [Related]
15. A case report of remarkable response to association of radiofrequency ablation with subsequent Atezolizumab in stage IV nonsmall cell lung cancer.
Yin J; Dong J; Gao W; Wang Y
Medicine (Baltimore); 2018 Nov; 97(44):e13112. PubMed ID: 30383701
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of pleural effusion caused by lung carcinoma with circular intrapleural hyperthermic perfusion and its mechanism].
Kang M; Zhou L; Lin P
Zhonghua Yi Xue Za Zhi; 2001 Oct; 81(19):1176-9. PubMed ID: 11769704
[TBL] [Abstract][Full Text] [Related]
17. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
18. Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.
Zhang Y; Zhao M; Cao S; Zhang X; Du Y
Thorac Cancer; 2020 Sep; 11(9):2717-2722. PubMed ID: 32656988
[TBL] [Abstract][Full Text] [Related]
19. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S; Wu L; Jian H; Cheng Y; Wang Q; Fang J; Wang Z; Hu Y; Han L; Sun M; Miao L; Ding C; Cui J; Wang K; Li B; Li X; Ye F; Liu A; Pan Y; Cang S; Zhou H; Sun X; Shen Y; Wang S; Zhang W; He Y
Lancet Respir Med; 2023 Jul; 11(7):624-636. PubMed ID: 37156249
[TBL] [Abstract][Full Text] [Related]
20. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
Ilie M; Juco J; Huang L; Hofman V; Khambata-Ford S; Hofman P
Cancer Cytopathol; 2018 Apr; 126(4):264-274. PubMed ID: 29411536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
